RADX

0.63046.33%
PE

Paul Edward-Alexander Hopper

Founder & Executive Chairman

Mr. Paul Edward-Alexander Hopper, B.A (UNSW), A.S.I.A, FAICD served as Independent Director at Scopus BioPharma Inc. since June 2020 until May 18, 2022 and served as its Co-Chairman until October 2020. He is Founder of Radiopharm Theranostics Limited and is its Executive Chairman since February 11, 2021. He served as Executive Chairman of Chimeric Therapeutics Limited since February 2021 until November 25, 2025 and served as its Director since February 2, 2020 until November 25, 2025. Mr. Hopper is the Founder of Chimeric Therapeutics Limited since 2019. He served as Non-Executive Chairman at Arovella Therapeutics Limited (formerly known as Suda Pharmaceuticals Ltd) since January 02, 2020 until June 30, 2022. Mr. Hopper has experience in the management and funding of biotechnology and healthcare public companies both as Chief Executive Officer and Director in Australia and the United States. His sector experience has covered a number of therapeutic areas with a particular emphasis on immunotherapy and cancer vaccines. He also has extensive capital markets experience in equity and debt raisings in Australia, Asia, Europe and the United States. He served as Executive Chairman of Arovella Therapeutics Limited (formerly known as Suda Pharmaceuticals Ltd) since September 23, 2019 until January 02, 2020 and served as its Non-Executive Chairman since May 15, 2019 until September 23, 2019. Mr. Hopper serves as the Head of Australian Desk of Cappello Group, Inc.; Managing Director of Cappello Group, Inc.; and Head of the Life Sciences and Healthcare Practice at Cappello Global, LLC. Mr. Hopper also serves as the Chief Operating Officer at Biolife Science Limited. He served as the Chief Operating Officer at Acuvax Limited. Mr. Hopper also served as its Chief Executive Officer from August 14, 2003 to February 2005 and its Managing Director from October 1, 2003 to February 2005. He served as the Chief Executive Officer and President at Avantogen Oncology, Inc. Mr. Hopper served as the Chief Executive Officer at Viralytics Limited since July 24, 2012 and Nextrata Energy Inc. since August 22, 2005. He served as a Director of Business Development at Advanced Biotherapy, Inc. since March 2005. Mr. Hopper also served as the Chief Executive Officer and Director of Vaccinoma Australia Limited. He serves as Executive Chairman of Imugene Limited and has been its Director since October 31, 2012. He Founded Imugene Limited in October 2012. He serves as a Director of Biolife Science Qld Limited, Vaccinoma, Acuvax Limited and Biolife Science Limited. Mr. Hopper served as the Chairman of Avantogen Oncology, Inc. through June 20, 2005. Mr. Hopper served as an Executive Chairman of Cell Aquaculture Ltd. from August 15, 2007 to March 2008 and Bone Medical Ltd. from July 1, 2005 to July 2007. He served as the Non-Executive Chairman at Viralytics Limited since September 4, 2008 until June 20, 2018. He has been a Non-Executive Director of Avantogen Oncology, Inc. since June 20, 2005. Mr. Hopper has been an Executive Director of Virax Holdings Limited since December 1, 2014. He served as a Non-Executive Director of Viralytics Limited since July 12, 2007 until June 21, 2018. He served as a Director of Somnomed Limited. Mr. Hopper served as a Director of Medaire Inc. through January 31, 2003. He served as an Independent Director of Fibrocell Science Inc. from September 2009 to November 2010. He served as a Non-Executive Director at Prescient Therapeutics Limited from May 2014 until January 2, 2020 and served as its Executive Director since December 01, 2014 until 30 June 2017. Mr. Hopper served as a Director of Advanced Biotherapy, Inc. since November 2005 and Acuvax Limited October 1, 2003. He served as a Non-Executive Director of pSivida Corp. from July 2008 to January 17, 2014 and until March 2012. Mr. Hopper serves as the Chairman of the Board of the Californian Chapter of the American Australian Association. He has served as the Chairman, Director or Chief Executive Officer of 12 public companies in Australia and the United States. He had been Director of Arovella Therapeutics Limited (formerly known as Suda Pharmaceuticals Ltd) since May 15, 2019 to June 2022. He received a B.A. in Political Science from the University of New South Wales. Mr. Hopper also received a Postgraduate degree from the Harvard University Graduate School of Business and The Securities Institute of Australia.

Positions